NCT03430089View on ClinicalTrials.gov

Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

June 6, 2019

Study Completion Date

June 6, 2019

Conditions
InfluenzaFlu
Interventions
BIOLOGICAL

Shz QIV 0.25 mL, 2 doses

Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.

BIOLOGICAL

Shz QIV 0.5 mL, 2 doses

Administered intramuscularly into the deltoid muscle, 28 days apart

BIOLOGICAL

Shz QIV 0.5 mL, single dose

Administered intramuscularly into the deltoid muscle.

Trial Locations (1)

Unknown

Investigational Site 002, Xishuangbanna Dai Autonomous Prefecture

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03430089 - Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine | Biotech Hunter | Biotech Hunter